Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592806 | SCV000703943 | uncertain significance | not provided | 2016-12-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001860175 | SCV002125316 | likely benign | Deficiency of ferroxidase | 2024-09-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004975696 | SCV005566978 | uncertain significance | Inborn genetic diseases | 2024-07-23 | criteria provided, single submitter | clinical testing | The c.716A>T (p.Y239F) alteration is located in exon 4 (coding exon 4) of the CP gene. This alteration results from a A to T substitution at nucleotide position 716, causing the tyrosine (Y) at amino acid position 239 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |